本页面由Tiger Trade Technology Pte. Ltd.提供服务

Altamira Therapeutics Ltd.

0.3000
0.0000
成交量:- -
成交额:27.71万
市值:113.36万
市盈率:-0.16
高:0.3000
开:0.3000
低:0.3000
收:0.3000
52周最高:3.60
52周最低:0.3000
股本:377.85万
流通股本:375.78万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.9065
每股收益(LYR):-9.3533
净资产收益率:-368.78%
总资产收益率:-57.15%
市净率:0.18
市盈率(LYR):-0.03

数据加载中...

2023/03/13

SEC问询函

CORRESP [Cover] - Correspondence
2023/03/13

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/03/09

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/03/08

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/03/07

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/03/01

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/28

SEC问询函

CORRESP [Cover] - Correspondence
2023/02/28

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/16

招股说明书

F-1 - Registration statement for certain foreign private issuers
2023/01/18

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/22

SEC问询函

CORRESP [Cover] - Correspondence
2022/12/16

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/09/29

SEC问询函

CORRESP [Cover] - Correspondence
2022/09/13

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/13

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/22

SEC问询函

CORRESP [Cover] - Correspondence
2022/04/12

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/15

SEC问询函

CORRESP [Cover] - Correspondence
2022/02/08

招股说明书

F-1 - Registration statement for certain foreign private issuers
2021/12/07

SEC问询函

CORRESP [Cover] - Correspondence